Nosyk B, Min J E, Pearce L A, Zhou H, Homayra F, Wang L, Piske M, McCarty D, Gardner G, O'Briain W, Wood E, Daly P, Walsh T, Henry B
Centre for Health Evaluation and Outcome Sciences (CHÉOS), St Paul's Hospital, 588-1081 Burrard St, Vancouver, British Columbia V6Z 1Y6, Canada; Faculty of Health Sciences, Simon Fraser University, Blusson Hall, Rm 11300 8888 University Drive, Burnaby, British Columbia V5A 1S6, Canada.
Centre for Health Evaluation and Outcome Sciences (CHÉOS), St Paul's Hospital, 588-1081 Burrard St, Vancouver, British Columbia V6Z 1Y6, Canada.
Drug Alcohol Depend. 2022 Apr 1;233:109375. doi: 10.1016/j.drugalcdep.2022.109375. Epub 2022 Feb 24.
BACKGROUND: Performance measurement provides an evidence-based means to inform development of interventions to improve the quality of care for people who use opioids. We aimed to develop and assess the predictive validity of health system performance measures for opioid use disorder (OUD) in British Columbia (BC), Canada. METHODS: Performance measures were generated using retrospective population-level administrative datasets (both provincial and regional) and publicly-reported retrospective data according to four domains (care engagement, clinical guideline compliance, integration, and healthcare utilization). The adjusted odds ratio was estimated via generalized linear mixed models to determine predictive validity for all-cause hospitalization or mortality within 6 months of measurement. FINDINGS: A total of 102 performance measures were constructed. We identified 55,470 diagnosed PWOUD, and 39,456 ever engaged in opioid agonist treatment (OAT). We found divergent rates of treatment for concurrent conditions (7.4% for alcohol use disorder to 80.1% for HIV/AIDS), low levels of linkage to OAT and other outpatient care following acute care, and increasing levels of service provision, including increases in OAT prescribers and pharmacies, naloxone kit distribution and overdose prevention site visitation. Our analyses on the predictive validity measures largely supported a priori hypotheses on the direction of effect on the outcome. CONCLUSIONS: We identified a range of priorities to improve the quality of care for PWOUD, with critical gaps in linkage to care through acute care settings and long-term engagement in OAT. The proposed measures can be derived for geographic and clinical subgroups and updated over time, providing a basis to monitor and evaluate efforts to address the public health burden of OUD.
背景:绩效评估提供了一种基于证据的方法,以指导干预措施的制定,从而提高阿片类药物使用者的护理质量。我们旨在开发并评估加拿大不列颠哥伦比亚省(BC)针对阿片类药物使用障碍(OUD)的卫生系统绩效指标的预测效度。 方法:根据四个领域(护理参与、临床指南依从性、整合以及医疗保健利用),利用回顾性人群水平行政数据集(省级和地区级)以及公开报告的回顾性数据生成绩效指标。通过广义线性混合模型估计调整后的优势比,以确定在测量后6个月内全因住院或死亡的预测效度。 结果:共构建了102项绩效指标。我们确定了55470例确诊的患有阿片类药物使用障碍的患者(PWOUD),以及39456例曾接受阿片类激动剂治疗(OAT)的患者。我们发现并发疾病的治疗率存在差异(酒精使用障碍为7.4%,而艾滋病毒/艾滋病为80.1%),急性护理后与OAT及其他门诊护理的联系水平较低,以及服务提供水平不断提高,包括OAT处方医生和药房数量增加、纳洛酮试剂盒分发以及过量用药预防点就诊人次增加。我们对预测效度指标的分析在很大程度上支持了关于对结果影响方向的先验假设。 结论:我们确定了一系列优先事项,以提高对PWOUD的护理质量,在通过急性护理环境与护理的联系以及长期参与OAT方面存在重大差距。所提议的指标可针对地理和临床亚组得出,并随时间更新,为监测和评估应对OUD公共卫生负担的努力提供依据。
Drug Alcohol Depend. 2021-8-1
Drug Alcohol Depend. 2018-5-29
Drug Alcohol Depend. 2019-12-11
Drug Alcohol Depend Rep. 2025-4-23
J Appl Stat. 2024-2-9